BioCentury
ARTICLE | Clinical News

TB Alliance starts pivotal trial of four-drug regimen

August 28, 2018 8:43 PM UTC

The Global Alliance for TB Drug Development (TB Alliance) began the pivotal Phase IIc SimpliciTB trial evaluating an oral four-drug regimen called BPaMZ to treat tuberculosis.

SimpliciTB will compare BPaMZ, which comprises a once-daily combination of Sirturo bedaquiline, pretomanid (PA-824), moxifloxacin and pyrazinamide, for four months to a once-daily combination of the generics isoniazid, rifampicin, pyrazinamide and ethambutol (HRZE) for six months in patients with drug-sensitive TB. Moxifloxacin and pyrazinamide are also generics...